Reading this on a mobile device? Try our optimized mobile version here:

February 18, 2013
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • FDA accelerates review of ViiV's HIV/AIDS drug dolutegravir
    ViiV Healthcare, a joint venture of GlaxoSmithKline, Pfizer and Shionogi, obtained priority-review status from the FDA for its investigational daily AIDS/HIV treatment dolutegravir. The drug is an integrase inhibitor that keeps the virus out of cells. The FDA is set to decide on the drug's approval by Aug. 17. Yahoo/Reuters (2/16) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • Applied Spectral's automated gene scanner wins FDA approval
    Applied Spectral Imaging obtained FDA approval to market its GenASIs Scan & Analysis microscopy platform to aid ALK gene analysis for selection of lung cancer treatment. The scanner can be used in genetic analysis of samples with the Abbott Vysis ALK Break Apart FISH Probe test. Abbott's assay is used to determine the presence of ALK-positive nonsmall-cell lung cancer, which may respond to Pfizer's Xalkori. GenomeWeb Daily News (free registration) (2/15) LinkedInFacebookTwitterEmail this Story
  • Astellas-Aveo's tivozanib extends survival in kidney cancer trial
    Patients with kidney cancer who took Astellas and Aveo Pharmaceuticals' tivozanib survived without their disease worsening longer than patients who took Bayer and Onyx Pharmaceuticals' Nexavar, or sorafenib, while overall surival was comparable, a clinical study found. The FDA is expected to decide on tivozanib's approval by July 28. PharmaTimes (U.K.) (2/14) LinkedInFacebookTwitterEmail this Story
  • Study to explore stem cell therapy for diabetic retinopathy
    A European Union-supported study will explore the use of adult bone marrow stem cells in treating diabetic retinopathy. Researchers are set to grow the cells in the laboratory and plan to transplant them in patients in an attempt to repair damaged blood vessels and retinas and to restore vision. Human trials are slated to be conducted in Denmark after preclinical tests at several sites in Europe. (U.K.) (2/14) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Food & Agriculture 
  Hot Topics 

Top five news stories selected by BIO SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Industrial & Environmental 
  • Calif. agency gives $17.2M to transportation projects
    The California Energy Commission awarded $17.2 million to companies developing cleaner transportation technologies, including biofuels, under its Alternative and Renewable Fuel and Vehicle Technology Program. The program is expected to give about $90 million this fiscal year. (2/15) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

You will become as small as your controlling desire; as great as your dominant aspiration."
--James Allen,
British author

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information